JP2008519042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519042A5 JP2008519042A5 JP2007540074A JP2007540074A JP2008519042A5 JP 2008519042 A5 JP2008519042 A5 JP 2008519042A5 JP 2007540074 A JP2007540074 A JP 2007540074A JP 2007540074 A JP2007540074 A JP 2007540074A JP 2008519042 A5 JP2008519042 A5 JP 2008519042A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- virus
- antigen
- influenza virus
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712461 unidentified influenza virus Species 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 46
- 239000000427 antigen Substances 0.000 claims description 44
- 102000036639 antigens Human genes 0.000 claims description 44
- 108091007433 antigens Proteins 0.000 claims description 44
- 230000002163 immunogen Effects 0.000 claims description 36
- 241000700605 Viruses Species 0.000 claims description 29
- 210000001821 langerhans cell Anatomy 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 26
- 230000003053 immunization Effects 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 241000271566 Aves Species 0.000 claims description 4
- 241000712431 Influenza A virus Species 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 4
- 239000004621 biodegradable polymer Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000003501 vero cell Anatomy 0.000 claims description 4
- 241000713196 Influenza B virus Species 0.000 claims description 3
- 230000005847 immunogenicity Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 14
- 239000000185 hemagglutinin Substances 0.000 description 13
- 101710154606 Hemagglutinin Proteins 0.000 description 12
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 12
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 12
- 101710176177 Protein A56 Proteins 0.000 description 12
- 206010022000 influenza Diseases 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 210000002615 epidermis Anatomy 0.000 description 7
- 229960003971 influenza vaccine Drugs 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 238000010255 intramuscular injection Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 3
- -1 aluminum salts Chemical class 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 208000007056 sickle cell anemia Diseases 0.000 description 3
- 229940031418 trivalent vaccine Drugs 0.000 description 3
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 229910001651 emery Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62497304P | 2004-11-03 | 2004-11-03 | |
| PCT/US2005/039982 WO2006062637A2 (en) | 2004-11-03 | 2005-11-03 | Influenza vaccination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011219630A Division JP2012001565A (ja) | 2004-11-03 | 2011-10-03 | インフルエンザワクチン接種 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519042A JP2008519042A (ja) | 2008-06-05 |
| JP2008519042A5 true JP2008519042A5 (https=) | 2011-11-24 |
Family
ID=36578359
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540074A Pending JP2008519042A (ja) | 2004-11-03 | 2005-11-03 | インフルエンザワクチン接種 |
| JP2011219630A Pending JP2012001565A (ja) | 2004-11-03 | 2011-10-03 | インフルエンザワクチン接種 |
| JP2014081555A Pending JP2014132035A (ja) | 2004-11-03 | 2014-04-11 | インフルエンザワクチン接種 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011219630A Pending JP2012001565A (ja) | 2004-11-03 | 2011-10-03 | インフルエンザワクチン接種 |
| JP2014081555A Pending JP2014132035A (ja) | 2004-11-03 | 2014-04-11 | インフルエンザワクチン接種 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20090004222A1 (https=) |
| EP (2) | EP2923711A1 (https=) |
| JP (3) | JP2008519042A (https=) |
| CN (1) | CN101076355A (https=) |
| AU (1) | AU2005314563B2 (https=) |
| CA (1) | CA2586690A1 (https=) |
| ES (1) | ES2542020T3 (https=) |
| HK (1) | HK1214534A1 (https=) |
| WO (1) | WO2006062637A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7566458B2 (en) | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| EP2471552B1 (en) | 2005-03-08 | 2015-05-06 | MedImmune, LLC | Reassortant influenza viruses |
| RU2523587C2 (ru) * | 2008-07-11 | 2014-07-20 | МЕДИММЬЮН, ЭлЭлСи | Варианты гемагглютинина и нейрамидазы вируса гриппа |
| CN102112151A (zh) * | 2008-07-30 | 2011-06-29 | 久光制药株式会社 | 微针装置及由微针装置使日本脑炎病毒抗原的功效升高的方法 |
| EP4241785B1 (en) * | 2011-09-20 | 2026-01-28 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| BR112015018014A2 (pt) * | 2013-02-01 | 2017-07-11 | Glaxosmithkline Biologicals Sa | liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| CA3088485A1 (en) * | 2018-01-18 | 2019-07-25 | Etherna Immunotherapies Nv | Lipid nanoparticles |
| US12545718B2 (en) | 2019-04-24 | 2026-02-10 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| JP2023523952A (ja) | 2020-04-28 | 2023-06-08 | ティコナ・エルエルシー | マイクロニードルアセンブリ |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1122527A (en) | 1979-05-15 | 1982-04-27 | Karen K. Brown | Influenza vaccine production in liquid cell culture |
| CA2017507C (en) * | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| NZ240369A (en) | 1990-10-30 | 1993-09-27 | Daiichi Seiyaku Co | Muramyl dipeptide derivatives and vaccine compositions |
| CA2156525A1 (en) | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| US5776468A (en) * | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
| GB9500788D0 (en) | 1995-01-16 | 1995-03-08 | Medeva Holdings Bv | Vaccine compositions |
| ATE213646T1 (de) | 1995-10-20 | 2002-03-15 | Yissum Res Dev Co | Grippe-impfstoff |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| US6843781B2 (en) * | 1999-10-14 | 2005-01-18 | Becton, Dickinson And Company | Intradermal needle |
| GB0017999D0 (en) | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
| CA2438960A1 (en) * | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
| EP2281573A3 (en) * | 2001-02-23 | 2011-12-07 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
| US20020193729A1 (en) * | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
| MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| CN1253220C (zh) * | 2001-06-29 | 2006-04-26 | 贝克顿迪肯森公司 | 通过微管在真皮内输入疫苗和基因治疗剂 |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| US7588774B2 (en) * | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
| US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
| KR20060135931A (ko) * | 2004-04-01 | 2006-12-29 | 알자 코포레이션 | 인플루엔자 백신의 경피전달 장치 및 방법 |
| EP2674486A1 (en) * | 2007-06-18 | 2013-12-18 | MedImmune, LLC | Influenza B viruses having alterations in the hemaglutinin polypeptide |
-
2005
- 2005-11-03 US US11/667,055 patent/US20090004222A1/en not_active Abandoned
- 2005-11-03 JP JP2007540074A patent/JP2008519042A/ja active Pending
- 2005-11-03 WO PCT/US2005/039982 patent/WO2006062637A2/en not_active Ceased
- 2005-11-03 AU AU2005314563A patent/AU2005314563B2/en not_active Expired
- 2005-11-03 EP EP15154014.3A patent/EP2923711A1/en not_active Withdrawn
- 2005-11-03 EP EP05823432.9A patent/EP1807116B1/en not_active Expired - Lifetime
- 2005-11-03 CN CNA200580042407XA patent/CN101076355A/zh active Pending
- 2005-11-03 ES ES05823432.9T patent/ES2542020T3/es not_active Expired - Lifetime
- 2005-11-03 CA CA002586690A patent/CA2586690A1/en not_active Abandoned
-
2011
- 2011-10-03 JP JP2011219630A patent/JP2012001565A/ja active Pending
-
2014
- 2014-04-11 JP JP2014081555A patent/JP2014132035A/ja active Pending
-
2015
- 2015-03-30 US US14/673,644 patent/US10112979B2/en not_active Expired - Lifetime
-
2016
- 2016-03-08 HK HK16102625.1A patent/HK1214534A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014132035A (ja) | インフルエンザワクチン接種 | |
| Quan et al. | Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles | |
| Vassilieva et al. | Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature | |
| JP5712126B2 (ja) | 遅延型追加刺激免疫処置に対する迅速な応答 | |
| Skountzou et al. | Skin immunization with influenza vaccines | |
| WO2017122635A1 (ja) | 固定化ウイルス粒子を含むワクチン | |
| TWI801328B (zh) | 包括咪喹莫特的局部調配物之用途 | |
| JP2008519042A5 (https=) | ||
| CN101450209B (zh) | 透皮免疫流感多价疫苗的制备及其方法 | |
| CN114761040A (zh) | 用于增强对疫苗接种的免疫反应和改善疫苗生产的组合物和方法 | |
| Glück | Intranasal immunization against influenza | |
| CN101754770B (zh) | 皮内流感疫苗 | |
| JP2010529166A5 (https=) | ||
| Zhang et al. | Immunological effect of subunit influenza vaccine entrapped by liposomes | |
| Carey | A new look at influenza vaccination |